Stocktoria
NEKTAR THERAPEUTICS NKTR
NEKTAR THERAPEUTICS financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M | $152.9M | $114.6M | $1.2B | $307.7M | $165.4M |
| R&D expense | $117.3M | $120.9M | $114.2M | $218.3M | $400.3M | $408.7M | $434.6M | $399.5M | $268.5M | $203.8M |
| Operating income | -$140.1M | -$105.2M | -$263.7M | -$376.2M | -$446.1M | -$425.1M | -$440.0M | $687.9M | -$59.6M | -$112.9M |
| Interest expense | — | — | — | $0 | $0 | $6.9M | $21.3M | $21.6M | $22.1M | $22.5M |
| Income tax | -$138,000 | -$239,000 | -$200,000 | $3.2M | $557,000 | $493,000 | $613,000 | $1.4M | $616,000 | $876,000 |
| Net income | -$164.1M | -$119.0M | -$276.1M | -$368.2M | -$523.8M | -$444.4M | -$440.7M | $681.3M | -$96.7M | -$153.5M |
| EPS (diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 |
| Operating cash flow | -$208.5M | -$175.7M | -$192.6M | -$304.0M | -$412.7M | -$313.3M | -$328.7M | $718.2M | -$80.4M | -$117.0M |
| Free cash flow | -$208.7M | -$177.2M | -$193.5M | -$309.7M | -$427.6M | -$320.5M | -$355.0M | $704.0M | -$90.1M | -$123.4M |
| Cash & equivalents | $15.1M | $44.3M | $35.3M | $88.2M | $25.2M | $199.0M | $96.4M | $194.9M | $4.8M | $59.6M |
| Inventory | $0 | $0 | $16.1M | $19.2M | $15.8M | $15.3M | $12.7M | $11.4M | $10.7M | $11.1M |
| Total assets | $280.4M | $303.9M | $398.0M | $710.6M | $1.1B | $1.5B | $2.0B | $2.2B | $508.9M | $568.9M |
| Total liabilities | $190.6M | $243.1M | $267.0M | $344.0M | $437.7M | $461.5M | $572.0M | $432.6M | $421.0M | $480.7M |
| Shareholders' equity | $89.8M | $60.7M | $131.0M | $366.6M | $679.5M | $1.1B | $1.4B | $1.7B | $87.8M | $88.1M |
Growth · year-over-year · Revenue CAGR -11.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -43.9% | +9.2% | -2.1% | -9.7% | -33.4% | +33.4% | -90.4% | +287.8% | +86.0% | -28.3% |
| Net income growth | — | — | — | — | — | — | -164.7% | — | — | — |
| EPS growth | — | — | — | — | — | — | -166.7% | — | — | — |
| Free cash flow growth | — | — | — | — | — | — | -150.4% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.